The Safety and Feasibility of Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Locally Advanced Resectable Non-Small Cell Lung Cancer
Latest Information Update: 26 Apr 2023
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary) ; Sintilimab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- 20 Apr 2023 Planned End Date changed from 20 Jul 2023 to 31 Dec 2024.
- 20 Apr 2023 Planned primary completion date changed from 20 Jul 2023 to 31 Dec 2024.
- 20 Apr 2023 Status changed from not yet recruiting to recruiting.